CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.24 USD
+1.68 (3.08%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $56.21 -0.03 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRSP 56.24 +1.68(3.08%)
Will CRSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Other News for CRSP
3 Gene Editing Stocks Shaping the Future of Medicine
3 Gene Editing Stocks That Could Grow Your Wealth
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Crispr Therapeutics call volume above normal and directionally bullish
Blue Chips, Small Caps Extending Their Breakout